AWARD NUMBER: W81XWH-14-2-0128

TITLE: Safety and Efficacy of the BrainPort V100 Device in Individuals Blinded by Traumatic Injury

PRINCIPAL INVESTIGATOR: Patricia Grant, M.S.

CONTRACTING ORGANIZATION: Wicab, Inc. Middleton, WI 53562

REPORT DATE: December 2016

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012

### DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

| balk spectra distance         Date spectra         Date sp   | R   | EPORT DOC   | UMENTATIO  | N PAGE  |  | Form Approved<br>OMB No. 0704-0188  |
|--|---|---|--|---|--|---|
| December 2016         Final         25 Sep 2016           4. TITLE AND SUBTITLE         Safety and Efficacy of the BrainPort V100 Device in Individuals Blinded by Traumatic<br>Injury         Sa. CONTRACT NUMBER           Safety and Efficacy of the BrainPort V100 Device in Individuals Blinded by Traumatic<br>Injury         Sc. CONTRACT NUMBER           6. AUTHORIS)         Sc. PROGRAM ELLMENT NUMBER           9. AUTHORIS)         Sc. PROGRAM ELLMENT NUMBER           6. AUTHORIS)         Sc. TASK NUMBER           7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)         Sc. TASK NUMBER           7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)         Sc. TASK NUMBER           8. PERFORMING ORGANIZATION REPORT         NUMBER           8. STASK NUMPER         St. WORK UNT NUMBER           8. STASK NUMPER         St. WORK UNT NUMBER           9. SPONSORING / MONTORING AGENCY NAME(S) AND ADDRESS(ES)         Is. SPONSOR/MONITOR'S ACRONYM(S)           U.S. Army Medical Research and Matericl Command         Is. SPONSOR/MONITOR'S REPORT           For Dubrick, Maryland 21702 Soli2         Is. SPONSOR/MONITOR'S REPORT           12. DISTRIBUTON / AVAILABILITY STATEMENT         Approved for Public Release; Distribution Unlimited           13. SPONSOR/MONITOR'S ACRONY SUBJUTION System comprody substitution system in persons who are profoundly bid de to a traumatic independence in performance of the DrainPort@ V200 device, an ousrupic.           14   | completing and reviewing this co<br>Washington Headquarters Service<br>other provision of law, no person  | llection of information. Send come<br>es, Directorate for Information Ope   | ments regarding this burden estimate<br>rations and Reports (0704-0188), 12  | or any other aspect of this collection<br>215 Jefferson Davis Highway, Suite  | n of information, including<br>1204, Arlington, VA 2220  | data sources, gathering and maintaining the data needed, and<br>suggestions for reducing this burden to Department of Defense,<br>02-4302. Respondents should be aware that notwithstanding any   |
| 4. TITLE AND SUBTILE       1. Full       5. CONTRACT NUMBER         Safety and Efficacy of the BrainPort V100 Device in Individuals Blinded by Traumatic<br>Injury       5. CONTRACT NUMBER         Safety and Efficacy of the BrainPort V100 Device in Individuals Blinded by Traumatic<br>Injury       5. CONTRACT NUMBER         Safety and Efficacy of the BrainPort V100 Device in Individuals Blinded by Traumatic<br>Injury       5. CONTRACT NUMBER         Safety and Efficacy of the BrainPort V100 Device in Individuals Blinded by Traumatic<br>Injury       5. CONTRACT NUMBER         Safety and Efficacy of the BrainPort V100 Device in Individuals Blinded by Traumatic<br>Injury       5. CONTRACT NUMBER         Safety and Efficacy of the BrainPort V100 Device in Individuals Blinded by Traumatic<br>Injury       5. CONTRACT NUMBER         Safety and Efficacy of the BrainPort V100 Device in Individuals Blinded by Traumatic<br>Injury       5. CONTRACT NUMBER         Safety and Efficacy of the BrainPort V100 Device in Individuals Blinded by Traumatic<br>Injury       5. CONTRACT NUMBER         Safety and Efficacy of the BrainPort V100 Device in Individuals Blinded by Traumatic<br>MIDDLETON W153562-3500       8. PROFOCHNONTOR'S ACRONVM(S)         U.S. Army Medical Research and Materiel Command<br>Fort Detrick, Maryland 21702-5012       10. SPONSOR/MONITOR'S ACRONVM(S)         LDISTRBUTION / AVAILABILITY STATEMENT<br>Approved for Public Release; Distribution Unlimited       11. SPONSOR/MONITOR'S REPORT<br>NUMBER         13. SUPPERMENTARY NOTES       14. ABSTRACT<br>NUMBER Simultan, interation with devinte fram   |   |   |  |   |  |   |
| Safety and Efficacy of the BrainPort V100 Device in Individuals Blinded by Traumatic<br>Injury  S. GRANT NUMBER  W1XWH-14-2-0128  Sc. PROGRAM ELEMENT NUMBER  W1XWH-14-2-0128  Sc. PROGRAM ELEMENT NUMBER  A. AUTHOR(S)  Rich Hogle, M.S. rhogle@wicab.com  St. WICAB, INC  St. NORK UNIT NUMBER  St. VORK UNIT NUMBER  |   | 1 mai   |  |   |  |   |
| Injury       W81XWH-14-2-0128         Se. PROGRAM ELEMENT NUMBER       56. PROGRAM ELEMENT NUMBER         6. AUTIOR(S)       56. PROGRAM ELEMENT NUMBER         7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)       56. TASK NUMBER         7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)       8. PERFORMING ORGANIZATION REPORT         WICAB, INC       83.1 GREENWAY BLVD STE 100         MIDDLETON WI 53562-3500       9. PENPORGING ORGANIZATION REPORT         9. SPONSORING / MONTTORING AGENCY NAME(S) AND ADDRESS(ES)       10. SPONSOR/MONITOR'S ACRONVM(S)         U.S. Army Medical Research and Materiel Command       11. SPONSOR/MONITOR'S ACRONVM(S)         For Detrick, Maryland 21702-5012       11. SPONSOR/MONITOR'S ACRONVM(S)         12. DISTRIBUTION / AVAILABILITY STATEMENT       ADSTRACT         ADSTRACT       Single-arm, multicenter clinical investigation. The aim of this study is to evaluate the functional performance of the BrainPort@         12. DISTRIBUTION / AVAILABILITY STATEMENT       ADSTRACT         13. SUPPLEMENTARY NOTES       14. ABSTRACT         14. ABSTRACT       Single-arm, multicenter clinical investigation. The aim of this study is to evaluate the functional performance of the BrainPort@         14. ABSTRACT       S. 6, 9, 90 12 ONORS.       11. SPONSOR/MONITOR'S REPORT         15. SUBJECT TERMS       11       Device-clause discrid device crasing induction or orelause discribed device  |   |   |  |   | 54.  | CONTRACT NUMBER   |
| 6. AUTHOR(S)       5d. PROJECT NUMBER         Patricia Grant, M.S. pgrant@wicab.com       5d. PROJECT NUMBER         Rich Hogle, M.S. thogle@wicab.com       0010378679USA         5c. TASK NUMBER       5f. WORK UNIT NUMBER         7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)       8. PERFORMING ORGANIZATION REPORT         WICAB, INC       8.313 GREENWAY BLVD STE 100         MIDDLETON WI 53562-3500       10. SPONSORMONITORING AGENCY NAME(S) AND ADDRESS(ES)         U.S. Army Medical Research and Materiel Command       11. SPONSORMONITOR'S ACRONYM(S)         Fort Detrick, Maryland 21702-5012       11. SPONSORMONITOR'S REPORT NUMBER(S)         12. DISTRUCTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited       11. SPONSORMONITOR'S REPORT NUMBER(S)         13. SUPTLEMENTIARY NOTES       14. ABSTRACT       11. SPONSOR/MONITOR'S REPORT NUMBER is designed to enhance independence in dependence  |   |   |  | ls Blinded by Trauma  |  |   |
| Patricia Grant, M.S. pgrunt@wicab.com       0010378679USA         Rich Hogle, M.S. rhogle@wicab.com       5: TASK NUMBER         7: PERFORMING ORGANIZATION NAME(\$) AND ADDRESS(E\$)       8: PERFORMING ORGANIZATION REPORT MUMBER         7: PERFORMING ORGANIZATION NAME(\$) AND ADDRESS(E\$)       8: PERFORMING ORGANIZATION REPORT MUMBER         8313 GREENWAY BLVD STE 100       10: SPONSORING / MONITORING AGENCY NAME(\$) AND ADDRESS(E\$)       10: SPONSOR/MONITOR'S ACRONYM(\$)         9: SPONSORING / MONITORING AGENCY NAME(\$) AND ADDRESS(E\$)       10: SPONSOR/MONITOR'S ACRONYM(\$)         12: SPENEMENTARY MONTOR'S ACCONYM(\$)       11: SPONSOR/MONITOR'S ACRONYM(\$)         13: SUPPLEMENTION / AVAILABILITY STATEMENT       NUMBER         Approved for Public Release; Distribution Unlimited       13: SPONSOR/MONTOR'S REPORT NUMBER(\$)         13: SUPPLEMENTIARY NOTES       14: ABSTRACT         14: ABSTRACT       Taim of this study is to evaluate the functional performance of the BrainPort(\$)         V200 device, an on-surgical, FDA approved, sensory substitution system, in persons who are profoundly bildue to a traumatic injury (cortical or ocular). The device, which provide visual information via clearcy environments for the set 12 months. Functional performance of the BrainPort(\$)         V200 device, a on - surgical, FDA approved, sensory substitution system, in persons who are profoundly bilance independence in performing activities of daily life. Nine out of the 20 projected participants have been enrolled across study sites. Participants have received ten hours of device training  |   |   |  |   | 5c. ]  | PROGRAM ELEMENT NUMBER  |
| Rich Hogle, M.S. mogle@wicab.com       0010378679USA         5. TASK NUMBER       5. VORK UNTI NUMBER         7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)       8. PERFORMING ORGANIZATION REPORT NUMBER         WICAB, INC       8313 GREENWAY BLVD STE 100         MIDDLETON WI 53562-3500       9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)       10. SPONSOR/MONITOR'S ACRONYM(S)         U.S. Army Medical Research and Materiel Command       11. SPONSOR/MONITOR'S ACRONYM(S)         Fort Detrick, Maryland 21702-5012       11. SPONSOR/MONITOR'S REPORT NUMBER(S)         12. DISTRIBUTION / AVAILABILITY STATEMENT       Approved for Public Release; Distribution Unlimited         13. SUPPLEMENTARY NOTES       14. ABSTRACT         This study is a prospective, single-arm, multicenter clinical investigation. The aim of this study is to evaluate the functional performance of the BrainPort@V20 device, anon-surgical PLA Dapoproved, sensory substitution system, in persons who are profoundly blind due to a traumatic injury (cortical or ocular). The device, which provides visual information via electrotactile simulation on the tongue, is designed to enhance independence in performing activities of datily file. Nine out of the 20 orgice-datily and bave been emploid across study site. Participants have received ten house of device training. Follow-up assessments will be completed at 3, 6, 9, and 12 months. The psychosocial impact of assistive devices, assistive devices and post-device training. Follow-up assessing and post-device training. Follow-up assessing and post-device training. Follow-up assessing and post-device training. Follow-up associaad with the BrainPort V  | 6. AUTHOR(S)  |   |  |   | 5d.  | PROJECT NUMBER  |
| Se. TASK NUMBER         7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)         WICAB, INC         8313 GREENWAY BLVD STE 100         MIDDLETON WI 53562-3500         9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)         10. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)         11. SPONSOR/MONITOR'S ACRONYM(S)         U.S. Army Medical Research and Materiel Command         Fort Detrick, Maryland 21702-5012         12. DISTRIBUTION / AVAILABILITY STATEMENT         Approved for Public Release: Distribution Unlimited         13. SUPPLEMENTARY NOTES         14. ABSTRACT         1bis study is a prospective, single-arm, multicenter clinical investigation. The aim of this study is to evaluate the functional performance of the BrainPort@ V200 device, a non-surgical, FDA approved, for the 20 project or particulants have been enrolled across study sites. Participants have reviewed ten hours of device training and have taken the device home to use in their everyday environments for the next 12 months. Functional performance of the BrainPort@ V200 device, a non-surgical, FDA approved, encer setuation and mobility, and word identification are encered to a post-evice were assessed at baseline and will be measured a second the study. Device-related adveres events will be completed at 3, 6, 9, and 12 months. The psychosocial impact of assistive devices and pace-leader device were assessed at baseline and will be measured a second the study. Device-related adveres events will be entrolled within the next quarter.         15. SUMECT TEMB       BrainPort V200. The remaining 11 particip   |   |   |  |   |  |   |
| SERVECT TERMS         SUBJECT TERMS  | Rich Hogle, M.S   | . <u>rhogle@wicab.con</u>   | <u>n</u>   |   | 00   | 010378679USA  |
| 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)       8. PERFORMING ORGANIZATION REPORT<br>NUMBER         WICAB, INC<br>8313 GREENWAY BLVD STE 100<br>MIDDLETON WI 53562-3500       10. SPONSOR/MONITOR'S ACRONYM(S)         9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)       10. SPONSOR/MONITOR'S ACRONYM(S)         U.S. Army Medical Research and Materiel Command<br>Fort Detrick, Maryland 21702-5012       11. SPONSOR/MONITOR'S REPORT<br>NUMBER(S)         12. DISTRIBUTION / AVAILABILITY STATEMENT<br>Approved for Public Release; Distribution Unlimited       13. SUPPLEMENTARY NOTES         14. ANSTRACT<br>This study is a prospective, single-arm, multicenter clinical investigation. The aim of this study is to evaluate the functional performance of the BrainPort@<br>V200 device, a non-surgical, EDA approved, sensory substitution system, in persons who are profoundly blind due to a traumatic injury (cortical or<br>ocular). The device, which provides visual information via electrotactile stimulation on the tongue, is designed to enhance independence in performing<br>activities of daily life. Nine out of the 20 projected participants have been enrolled across study sites. Participants have received ten hours of device<br>training and have taken the device home to use in their everyday environments for the next 12 months. Functional performance, Foloped<br>udentification, place setting identification, orientation and mobility, and word identification were assessed at baseline and post-device training, Follow-up<br>assessments will be completed at 3, 6, 9, and 12 months. The psychosocial impact of assistive devices and general self-efficace shale abaleline<br>and will be measured a second time at the end of the study. Device-related adverse events will be reported throughout the study to evaluate the risks<br>associated with the BrainPort V200. The rem  |   |   |  |   | 5e. '  | TASK NUMBER   |
| WICAB, INC       NUMBER         8313 GREENWAY BLVD STE 100       NUMBER         MIDDLETON WI 53562-3500       In SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)       In SPONSOR/MONITOR'S ACRONYM(S)         V.S. Army Medical Research and Materiel Command       In SPONSOR/MONITOR'S ACRONYM(S)       In SPONSOR/MONITOR'S REPORT         V.S. Army Medical Research and Materiel Command       In SPONSOR/MONITOR'S REPORT       In SPONSOR/MONITOR'S REPORT         V.D. DISTRIBUTION / AVAILABILITY STATEMENT       MUMBER(S)       In SPONSOR/MONITOR'S REPORT         13. SUPLEMENTARY NOTES       In Story as prospective, single-arm, multicenter clinical investigation. The aim of this study is to evaluate the functional performance of the BrainPort(@)         V200 device, a non-surgical, FDA approved, sensory substitution system, in persons who are profoundly blind due to a traumatic injury (cortical or ocular). The device, which provides visual information via electrotactic Buildiant on the tongue, is designed to enhance independence in performing activities of daily life. Nine out of the 20 projected participants have been enrolled across study sites. Participants have received ten hours of device training and have taken the device home to use in their every day environments for the next 12 months. Functional performance and post-device training. Follow-up assessments will be completed at 3, 6, 9, and 12 months. The psychosocial impact of assistive devices and specific approxed set baseline and post-device training. Follow-up assessments will be reported throughout the study to evaluate the risks associated with the BrainPort V200. The remaining 11 participants have been recruited and will be reported throughout   |   |   |  |   | 5f. V  | WORK UNIT NUMBER  |
| WICAB, INC       8313 GREENWAY BLVD STE 100         MIDDLETON WI 53562-3500       10. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)         9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)       10. SPONSOR/MONITOR'S ACRONYM(S)         U.S. Army Medical Research and Materiel Command       11. SPONSOR/MONITOR'S ACRONYM(S)         Fort Detrick, Maryland 21702-5012       11. SPONSOR/MONITOR'S REPORT NUMBER(S)         12. DISTRIBUTION / AVAILABILITY STATEMENT       Approved for Public Release; Distribution Unlimited         13. SUPPLEMENTARY NOTES       14. ADSTRACT         This study is a prospective, single-arm, multicenter clinical investigation. The aim of this study is to evaluate the functional performance of the BrainPort® V200 device, anon-surgical, PDA approved, sensory substitution system, in persons who are profoundly blind due to a traumatic injury (cortical or ocular). The device, which provides visual information via electrotactile stimulation on the tongue, is designed to enhance independence in performing activities of daily life. Nine out of the 20 projected participants have been enrolled across study sites. Participants have received ten hours of device training and have taken the device home to use in their everyday environments for the next 12 months. Functional performance measures of object identification, orientation and mobility, and word identification were assessed at baseline and post-device training. Follow-up assessments will be completed at 3. 6, 9, and 12 months. The psychosocial impact of assistive devices and general self-efficanes are been erclude adverse events will be reported throughout the study to evaluate the risks associated with the BrainPort V200. The remaining 11 participants have b   | 7. PERFORMING ORG   | GANIZATION NAME(S   | ) AND ADDRESS(ES)  |   |  |   |
| MIDDLETON WI 53562-3500       Io. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)       Io. SPONSORING / MONITORI'S ACRONYM(S)         U.S. Army Medical Research and Materiel Command       In. SPONSOR/MONITOR'S ACRONYM(S)       In. SPONSOR/MONITOR'S REPORT         Fort Detrick, Maryland 21702-5012       In. SPONSOR/MONITOR'S REPORT       NUMBER(S)         12. DISTRIBUTION / AVAILABILITY STATEMENT       Approved for Public Release; Distribution Unlimited         13. SUPPLEMENTARY NOTES       In. SUPPLEMENTARY NOTES         14. ABSTRACT       This study is a prospective, single-arm, multicenter clinical investigation. The aim of this study is to evaluate the functional performance of the BrainPort@ V200 device, a non-surgical, FDA approved, sensory substitution system, in persons who are profoundly blind due to a traumatic injury (cortical or ocular). The device, which provides visual information via electrotactile stimulation on the torque, is designed to enhance independence in performing activities of daily life. Nine received the hours of device training and have taken the device home to use in their everyday environments for the next 12 months. Functional performance measures of object daily life. Nine and mobility, and word identification were assessed at baseline and post-device related and word identification were assessed at baseline and post-device vice related the sudy. Device-related adverse events will be reported throughout the study to evaluate the risks associated with the BrainPort V200. The remaining 11 participants have been recruited and will be enrolled within the next quarter.         15. SUBJECT TERMS         BrainPort, V100, V200, blindness, visual impairment, assistive device, assistive techno   | WICAB, INC  |   |  |   |  |   |
| 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)       10. SPONSOR/MONITOR'S ACRONYM(S)         U.S. Army Medical Research and Materiel Command<br>Fort Detrick, Maryland 21702-5012       11. SPONSOR/MONITOR'S REPORT<br>NUMBER(S)         12. DISTRIBUTION / AVAILABILITY STATEMENT<br>Approved for Public Release; Distribution Unlimited       11. SPONSOR/MONITOR'S REPORT<br>NUMBER(S)         13. SUPPLEMENTARY NOTES       14. ADSTRACT         This study is a prospective, single-arm, multicenter clinical investigation. The aim of this study is to evaluate the functional performance of the BrainPort®<br>V200 device, a non-surgical, FDA approved, sensory substitution system, in persons who are profoundly blind due to a traumatic injury (cortical or<br>ocular). The device, which provides visual information via electrotactile stimulation on the tongue, is designed to enhance independence in performing<br>activities of daily life. Nine out of the 20 projected participants have been enrolled across study sites. Participants have received the hours of device<br>training and have taken the device home to use in their everyday environments for the next 12 months. Functional performance measures of object<br>identification, noi entation and mobility, and word identification were assessed at baseline and post-device training. Follow-up<br>assessments will be completed at 3, 6, 9, and 12 months. The psychosocial impact of assistive devices and general self-efficacy were assessed at baseline<br>and will be measured a second time at the end of the study. Device-related adverse verents will be enrolled throughout the study to evaluate the risks<br>associated with the BrainPort V200. The remaining 11 participants have been recruited and will be enrolled throughout the study to evaluate the risks<br>associated with the BrainPort V200, blindness, visual impairment, assistive device, assistive tech   | 8313 GREENW   | AY BLVD STE 1   | 00   |   |  |   |
| U.S. Army Medical Research and Materiel Command<br>Fort Detrick, Maryland 21702-5012 TI. SPONSOR/MONITOR'S REPORT<br>NUMBER(S)<br>12. DISTRIBUTION / AVAILABILITY STATEMENT<br>Approved for Public Release; Distribution Unlimited<br>13. SUPPLEMENTARY NOTES<br>14. ADSTRACT<br>This study is a prospective, single-arm, multicenter clinical investigation. The aim of this study is to evaluate the functional performance of the BrainPort®<br>V200 device, a non-surgical, FDA approved, sensory substitution system, in persons who are profoundly blind due to a traumatic injury (cortical or<br>ocular). The device, which provides visual information via electrotacitle stimulation on the torgue, is designed to enhance independence in performing<br>activities of daily life. Nine out of the 20 projected participants have been enrolled across study yites. Participants have received ten hours of device<br>training and have taken the device home to use in their everyday environments for the next 12 months. Functional performance measures of object<br>training and have taken the device home to use in their everyday environments for the next 12 months. Functional performance measures of object<br>training and have taken the device home to use in their everyday environments for the next 12 months. Functional performance measures of object<br>training and have taken the device home to use in their everyday environments for the next 12 months. Functional performance measures associated with the BrainPort V200. The remaining 11 participants have been recruited and will be enrolled within the next quarter.<br>15. SUBJECT TERMS<br>BrainPort, V100, V200, blindness, visual impairment, assistive device, assistive technology, visual aid, non-surgical<br>visual prosthetic, sensory substitution<br>16. SECURTY CLASIFICATION OF:<br>17. LIMITATION<br>18. NUMBER<br>Unclassified Unclassified Unclassified Unclassified 11<br>10. Brance freesponsible personsible personsible personsible personsible presonsible presonsible presonsible personsible presonsible presonsible presonsible presonsible presonsible | MIDDLETON W   | VI 53562-3500   |  |   |  |   |
| Fort Detrick, Maryland 21702-5012       II. SPONSOR/MONITOR'S REPORT NUMBER(S)         12. DISTRIBUTION / AVAILABILITY STATEMENT       Approved for Public Release; Distribution Unlimited         13. SUPPLEMENTARY NOTES       II. SPONSOR/MONITOR'S REPORT         14. ABSTRACT       This study is a prospective, single-arm, multicenter clinical investigation. The aim of this study is to evaluate the functional performance of the BrainPort® V200 device, a non-surgical, FDA approved, sensory substitution system, in persons who are profoundly blind due to a traumatic injury (cortical or ocular). The device, which provides visual information via electrotactile stimulation on the tongue, is designed to enhance independence in performing activities of daily life. Nine out of the 20 projected participants have been enrolled across study sites. Participants have received ten hours of device training and have taken the device home to use in their everyday environments for the next 12 months. Functional performance measures of object identification, place setting identification, orientation and mobility, and word identification were assessed at baseline and post-device training. Follow-up assessments will be completed at 3, 6, 9, and 12 months. The psychosocial impact of assistive devices and general self-efficacy were assessed at baseline and post-device training. Follow-up assessitated a second time at the end of the study. Device-related adverse events will be enrolled within the next quarter.         15. SUBJECT TERMS       Issumport V200, blindness, visual impairment, assistive device, assistive ter-hology, visual aid, non-surgical visual prosthetic, sensory substitution         16. SECURITY CLASSIFICATION OF:       17. LIMITATION OF ABSTRACT       18. NUMBER OF RESPONSIBLE PERSON USAMIRC </td <td>9. SPONSORING / MO</td> <td>NITORING AGENCY N</td> <td>NAME(S) AND ADDRES</td> <td>S(ES)</td> <td>10.</td> <td>SPONSOR/MONITOR'S ACRONYM(S)</td>   | 9. SPONSORING / MO  | NITORING AGENCY N   | NAME(S) AND ADDRES   | S(ES)   | 10.  | SPONSOR/MONITOR'S ACRONYM(S)  |
| Fort Detrick, Maryland 21702-5012       II. SPONSOR/MONITOR'S REPORT NUMBER(S)         12. DISTRIBUTION / AVAILABILITY STATEMENT       Approved for Public Release; Distribution Unlimited         13. SUPPLEMENTARY NOTES       II. SPONSOR/MONITOR'S REPORT         14. ABSTRACT       This study is a prospective, single-arm, multicenter clinical investigation. The aim of this study is to evaluate the functional performance of the BrainPort® V200 device, a non-surgical, FDA approved, sensory substitution system, in persons who are profoundly blind due to a traumatic injury (cortical or ocular). The device, which provides visual information via electrotactile stimulation on the tongue, is designed to enhance independence in performing activities of daily life. Nine out of the 20 projected participants have been enrolled across study sites. Participants have received ten hours of device training and have taken the device home to use in their everyday environments for the next 12 months. Functional performance measures of object identification, place setting identification, orientation and mobility, and word identification were assessed at baseline and post-device training. Follow-up assessments will be completed at 3, 6, 9, and 12 months. The psychosocial impact of assistive devices and general self-efficacy were assessed at baseline and post-device training. Follow-up assessitated a second time at the end of the study. Device-related adverse events will be enrolled within the next quarter.         15. SUBJECT TERMS       Issumport V200, blindness, visual impairment, assistive device, assistive ter-hology, visual aid, non-surgical visual prosthetic, sensory substitution         16. SECURITY CLASSIFICATION OF:       17. LIMITATION OF ABSTRACT       18. NUMBER OF RESPONSIBLE PERSON USAMIRC </td <td>U.S. Army Medical</td> <td>Research and Materi</td> <td>el Command</td> <td></td> <td></td> <td></td>  | U.S. Army Medical   | Research and Materi   | el Command   |   |  |   |
| Approved for Public Release; Distribution Unlimited  I3.SUPPLEMENTARY NOTES  I4. ABSTRACT  This study is a prospective, single-arm, multicenter clinical investigation. The aim of this study is to evaluate the functional performance of the BrainPort® V200 device, a non-surgical, FDA approved, sensory substitution system, in persons who are profoundly blind due to a traumatic injury (cortical or ocular). The device, which provides visual information via electrotactile stimulation on the tongue, is designed to enhance independence in performing activities of daily life. Nine out of the 20 projected participants have been enrolled across study sites. Participants have received ten hours of device training and have taken the device home to use in their everyday environments for the next 12 months. Functional performance measures of object identification, place setting identification, orientation and mobility, and word identification were assessed at baseline and post-device training. Follow-up assessments will be completed at 3, 6, 9, and 12 months. The psychosocial impact of assistive devices and general self-efficacy were assessed at baseline and will be measured a second time at the end of the study. Device-related adverse events will be reported throughout the study to evaluate the risks associated with the BrainPort V200. The remaining 11 participants have been recruited and will be enrolled within the next quarter.  IS.SUBJECT TERMS BrainPort, V100, V200, blindness, visual impairment, assistive device, assistive technology, visual aid, non-surgical visual prosthetic, sensory substitution  I.S.ECURITY CLASSIFICATION OF: I.S.ELINITATION I.S. MUMBER OF ABSTRACT I.S. Unclassified III   | -   |   |  |   | 11   | SPONSOD/MONITOD'S DEPODT  |
| 14. ABSTRACT         This study is a prospective, single-arm, multicenter clinical investigation. The aim of this study is to evaluate the functional performance of the BrainPort® V200 device, a non-surgical, FDA approved, sensory substitution system, in persons who are profoundly blind due to a traumatic injury (cortical or ocular). The device, which provides visual information via electrotactile stimulation on the tongue, is designed to enhance independence in performing activities of daily life. Nine out of the 20 projected participants have been enrolled across study sites. Participants have been to use in their everyday environments for the next 12 months. Functional performance measures of object identification, place setting identification, orientation and mobility, and word identification were assessed at baseline and post-device training. Follow-up assessments will be completed at 3, 6, 9, and 12 months. The psychosocial impact of assistive devices and general self-efficacy were assessed at baseline and will be ensaured a second time at the end of the study. Device-related adverse events will be reported throughout the study to evaluate the risks associated with the BrainPort V200. The remaining 11 participants have been recruited and will be enrolled within the next quarter.         IS. SUBJECT TERMS         BrainPort, V100, V200, blindness, visual impairment, assistive device, assistive technology, visual aid, non-surgical visual prosthetic, sensory substitution         Is. SUBJECT TERMS         BrainPort, V100, V200, blindness, visual impairment, assistive device, assistive technology, visual aid, non-surgical visual prosthetic, sensory substitution         IS. SUBJECT TERMS         BrainPort, V100, V200, blindness, vis  | Fort Detrick, Maryla  | and 21702-5012  |  |   |  |   |
| This study is a prospective, single-arm, multicenter clinical investigation. The aim of this study is to evaluate the functional performance of the BrainPort® V200 device, a non-surgical, FDA approved, sensory substitution system, in persons who are profoundly blind due to a traumatic injury (cortical or ocular). The device, which provides visual information via electrotactile stimulation on the tongue, is designed to enhance independence in performing activities of daily life. Nine out of the 20 projected participants have been enrolled across study sites. Participants have received ten hours of device training and have taken the device home to use in their everyday environments for the next 12 months. Functional performance measures of object identification, place setting identification, orientation and mobility, and word identification were assessed at baseline and post-device training. Follow-up assessments will be completed at 3, 6, 9, and 12 months. The psychosocial impact of assistive devices and general self-efficacy were assessed at baseline and will be measured a second time at the end of the study. Device-related adverse events will be reported throughout the study to evaluate the risks associated with the BrainPort V200. The remaining 11 participants have been recruited and will be enrolled within the next quarter.         IS. SUBJECT TERMS         BrainPort, V100, V200, blindness, visual impairment, assistive device, assistive teck-nology, visual aid, non-surgical visual prosthetic, sensory substitution         IS. SUBJECT TERMS         BrainPort, V100, V200, blindness, visual impairment, assistive device, assistive teck-nology, visual aid, non-surgical visual prosthetic, sensory substitution       Is. NUMBER of RESPONSIBLE PERSON       IPa. NAME OF RESPONSIBLE PERSON <t< td=""><td>12. DISTRIBUTION / A</td><td>AVAILABILITY STATE</td><td></td><td></td><td></td><td></td></t<>  | 12. DISTRIBUTION / A  | AVAILABILITY STATE  |  |   |  |   |
| BrainPort, V100, V200, blindness, visual impairment, assistive device, assistive technology, visual aid, non-surgical visual prosthetic, sensory substitution         16. SECURITY CLASSIFICATION OF:       17. LIMITATION OF ABSTRACT       19a. NAME OF RESPONSIBLE PERSON USAMRMC         a. REPORT       b. ABSTRACT       c. THIS PAGE       10       11         Unclassified       Unclassified       Unclassified       11       12       13  | <b>12. DISTRIBUTION / </b> Approved for Public  | AVAILABILITY STATE<br>c Release; Distributio  |  |   |  |   |
| visual prosthetic, sensory substitution         16. SECURITY CLASSIFICATION OF:         17. LIMITATION<br>OF ABSTRACT         0F ABSTRACT       18. NUMBER<br>OF PAGES         19b. TELEPHONE NUMBER (include area<br>code)         Unclassified       Unclassified  | <ul> <li>12. DISTRIBUTION / A<br/>Approved for Public</li> <li>13. SUPPLEMENTARY</li> <li>14. ABSTRACT<br/>This study is a prospect<br/>V200 device, a non-su<br/>ocular). The device, v<br/>activities of daily life.<br/>training and have take<br/>identification, place se<br/>assessments will be co<br/>and will be measured a</li> </ul>   | AVAILABILITY STATE<br>c Release; Distributio<br>Y NOTES<br>ctive, single-arm, multio<br>urgical, FDA approved,<br>which provides visual in<br>Nine out of the 20 proj<br>n the device home to us<br>etting identification, origon<br>pupleted at 3, 6, 9, and<br>a second time at the end   | n Unlimited<br>center clinical investigat<br>sensory substitution sys<br>formation via electrotac<br>ected participants have b<br>se in their everyday envi<br>entation and mobility, ar<br>12 months. The psycho<br>l of the study. Device-re   | tem, in persons who are<br>tile stimulation on the to<br>been enrolled across stud<br>ronments for the next 12<br>ad word identification w<br>social impact of assistiv<br>lated adverse events wil   | dy is to evaluate th<br>profoundly blind<br>ongue, is designed<br>dy sites. Participar<br>2 months. Function<br>ere assessed at ba<br>e devices and genu<br>l be reported throu  | NUMBER(S)<br>the functional performance of the BrainPort®<br>due to a traumatic injury (cortical or<br>to enhance independence in performing<br>ths have received ten hours of device<br>nal performance measures of object<br>seline and post-device training. Follow-up<br>eral self-efficacy were assessed at baseline<br>ughout the study to evaluate the risks   |
| 16. SECURITY CLASSIFICATION OF:     17. LIMITATION<br>OF ABSTRACT     18. NUMBER<br>OF PAGES     19a. NAME OF RESPONSIBLE PERSON<br>USAMRMC       a. REPORT     b. ABSTRACT     c. THIS PAGE     Unclassified     19b. TELEPHONE NUMBER (include area<br>code)       Unclassified     Unclassified     11     10b. TELEPHONE NUMBER (include area  | <ul> <li>12. DISTRIBUTION / A<br/>Approved for Public</li> <li>13. SUPPLEMENTARY</li> <li>14. ABSTRACT<br/>This study is a prospect<br/>V200 device, a non-su<br/>ocular). The device, v<br/>activities of daily life.<br/>training and have take<br/>identification, place se<br/>assessments will be co<br/>and will be measured a<br/>associated with the Br</li> <li>15. SUBJECT TERMS</li> </ul>   | AVAILABILITY STATE<br>c Release; Distributio<br>Y NOTES<br>ctive, single-arm, multio<br>urgical, FDA approved,<br>which provides visual in<br>Nine out of the 20 proj<br>n the device home to us<br>etting identification, orio<br>ompleted at 3, 6, 9, and<br>a second time at the end<br>ainPort V200. The remain   | n Unlimited<br>center clinical investigat<br>sensory substitution syst<br>formation via electrotac<br>ected participants have b<br>se in their everyday envi<br>entation and mobility, ar<br>12 months. The psycho<br>d of the study. Device-re<br>aining 11 participants ha                               | tem, in persons who are<br>tile stimulation on the to<br>been enrolled across stud-<br>ronments for the next 12<br>ad word identification w<br>social impact of assistiv<br>lated adverse events wil<br>we been recruited and w   | dy is to evaluate th<br>profoundly blind<br>ongue, is designed<br>dy sites. Participar<br>2 months. Function<br>ere assessed at ba<br>e devices and gene<br>l be reported throu<br>vill be enrolled wit  | NUMBER(S)<br>the functional performance of the BrainPort®<br>due to a traumatic injury (cortical or<br>to enhance independence in performing<br>its have received ten hours of device<br>nal performance measures of object<br>seline and post-device training. Follow-up<br>teral self-efficacy were assessed at baseline<br>ighout the study to evaluate the risks<br>hin the next quarter.   |
| a. REPORT     b. ABSTRACT     c. THIS PAGE     OF ABSTRACT     OF PAGES     USAMRMC       unclassified     unclassified     unclassified     11     19b. TELEPHONE NUMBER (include area  | <ul> <li>12. DISTRIBUTION / A<br/>Approved for Public</li> <li>13. SUPPLEMENTARY</li> <li>14. ABSTRACT<br/>This study is a prospective<br/>V200 device, a non-su<br/>ocular). The device, w<br/>activities of daily life.<br/>training and have take<br/>identification, place se<br/>assessments will be co<br/>and will be measured a<br/>associated with the Br</li> <li>15. SUBJECT TERMS<br/>BrainPort, V100</li> </ul>  | AVAILABILITY STATE<br>c Release; Distributio<br>Y NOTES<br>ctive, single-arm, multi<br>rrgical, FDA approved,<br>which provides visual in<br>Nine out of the 20 proj<br>n the device home to us<br>etting identification, orio<br>mpleted at 3, 6, 9, and<br>a second time at the end<br>ainPort V200. The remain<br>, V200, blindness  | n Unlimited<br>center clinical investigat<br>sensory substitution syst<br>formation via electrotac<br>ected participants have b<br>se in their everyday envi<br>entation and mobility, ar<br>12 months. The psycho<br>d of the study. Device-re<br>aining 11 participants ha                               | tem, in persons who are<br>tile stimulation on the to<br>been enrolled across stud-<br>ronments for the next 12<br>ad word identification w<br>social impact of assistiv<br>lated adverse events wil<br>we been recruited and w   | dy is to evaluate th<br>profoundly blind<br>ongue, is designed<br>dy sites. Participar<br>2 months. Function<br>ere assessed at ba<br>e devices and gene<br>l be reported throu<br>vill be enrolled wit  | NUMBER(S)<br>the functional performance of the BrainPort®<br>due to a traumatic injury (cortical or<br>to enhance independence in performing<br>its have received ten hours of device<br>nal performance measures of object<br>seline and post-device training. Follow-up<br>teral self-efficacy were assessed at baseline<br>ighout the study to evaluate the risks<br>hin the next quarter.   |
| a. REPORT     b. ABSTRACT     c. THIS PAGE       Unclassified     Unclassified       Unclassified     Unclassified   | <ul> <li>12. DISTRIBUTION / A<br/>Approved for Public</li> <li>13. SUPPLEMENTARY</li> <li>14. ABSTRACT<br/>This study is a prospective<br/>V200 device, a non-su<br/>ocular). The device, v<br/>activities of daily life.<br/>training and have take<br/>identification, place se<br/>assessments will be co<br/>and will be measured a<br/>associated with the Br</li> <li>15. SUBJECT TERMS<br/>BrainPort, V100<br/>visual prosthetic.</li> </ul>                         | AVAILABILITY STATE<br>c Release; Distributio<br>Y NOTES<br>ctive, single-arm, multi<br>rrgical, FDA approved,<br>which provides visual in<br>Nine out of the 20 proj<br>n the device home to us<br>etting identification, orio<br>mpleted at 3, 6, 9, and<br>a second time at the end<br>ainPort V200. The remain<br>, V200, blindness<br>, sensory substitut                     | n Unlimited<br>center clinical investigat<br>sensory substitution syst<br>formation via electrotac<br>ected participants have b<br>se in their everyday envi<br>entation and mobility, ar<br>12 months. The psycho<br>d of the study. Device-re<br>aining 11 participants ha                               | tem, in persons who are<br>tile stimulation on the to<br>been enrolled across stur<br>ronments for the next 12<br>ad word identification w<br>social impact of assistiv<br>lated adverse events wil<br>we been recruited and w  | dy is to evaluate th<br>profoundly blind<br>ongue, is designed<br>dy sites. Participar<br>2 months. Function<br>ere assessed at ba<br>e devices and gene<br>l be reported throw<br>vill be enrolled wit  | NUMBER(S)<br>the functional performance of the BrainPort®<br>due to a traumatic injury (cortical or<br>to enhance independence in performing<br>nts have received ten hours of device<br>nal performance measures of object<br>seline and post-device training. Follow-up<br>eral self-efficacy were assessed at baseline<br>ughout the study to evaluate the risks<br>hin the next quarter.<br>hnology, visual aid, non-surgical   |
| Unclassified Unclassified Unclassified   | <ul> <li>12. DISTRIBUTION / A<br/>Approved for Public</li> <li>13. SUPPLEMENTARY</li> <li>14. ABSTRACT<br/>This study is a prospective<br/>V200 device, a non-su<br/>ocular). The device, v<br/>activities of daily life.<br/>training and have take<br/>identification, place se<br/>assessments will be co<br/>and will be measured a<br/>associated with the Br</li> <li>15. SUBJECT TERMS<br/>BrainPort, V100<br/>visual prosthetic.</li> </ul>                         | AVAILABILITY STATE<br>c Release; Distributio<br>Y NOTES<br>ctive, single-arm, multi<br>rrgical, FDA approved,<br>which provides visual in<br>Nine out of the 20 proj<br>n the device home to us<br>etting identification, orio<br>mpleted at 3, 6, 9, and<br>a second time at the end<br>ainPort V200. The remain<br>, V200, blindness<br>, sensory substitut                     | n Unlimited<br>center clinical investigat<br>sensory substitution syst<br>formation via electrotac<br>ected participants have b<br>se in their everyday envi<br>entation and mobility, ar<br>12 months. The psycho<br>d of the study. Device-re<br>aining 11 participants ha                               | tem, in persons who are<br>tile stimulation on the to<br>been enrolled across stud-<br>ronments for the next 12<br>ad word identification w<br>social impact of assistiv<br>lated adverse events will<br>we been recruited and w<br>the assistive device<br>17. LIMITATION                | dy is to evaluate th<br>profoundly blind<br>ongue, is designed<br>dy sites. Participar<br>2 months. Function<br>ere assessed at ba<br>e devices and gend<br>l be reported throw<br>vill be enrolled wit<br>e, assistive tec<br>18. NUMBER              | NUMBER(S)<br>the functional performance of the BrainPort®<br>due to a traumatic injury (cortical or<br>to enhance independence in performing<br>nts have received ten hours of device<br>nal performance measures of object<br>seline and post-device training. Follow-up<br>eral self-efficacy were assessed at baseline<br>ughout the study to evaluate the risks<br>hin the next quarter.<br>hnology, visual aid, non-surgical<br>19a. NAME OF RESPONSIBLE PERSON  |
|  | <ul> <li>12. DISTRIBUTION / A<br/>Approved for Public</li> <li>13. SUPPLEMENTAR</li> <li>14. ABSTRACT<br/>This study is a prospect<br/>V200 device, a non-su<br/>ocular). The device, v<br/>activities of daily life.<br/>training and have take<br/>identification, place se<br/>assessments will be co<br/>and will be measured a<br/>associated with the Br</li> <li>15. SUBJECT TERMS<br/>BrainPort, V100<br/>visual prosthetic.</li> <li>16. SECURITY CLASS</li> </ul> | AVAILABILITY STATE<br>c Release; Distributio<br>Y NOTES<br>ctive, single-arm, multion<br>rgical, FDA approved,<br>which provides visual in<br>Nine out of the 20 proj<br>n the device home to us<br>etting identification, origon<br>public at 3, 6, 9, and<br>a second time at the end<br>ainPort V200. The remain<br>, V200, blindness<br>, sensory substitut<br>SIFICATION OF: | n Unlimited<br>center clinical investigat<br>sensory substitution syst<br>formation via electrotac<br>ected participants have b<br>se in their everyday envi<br>entation and mobility, ar<br>12 months. The psycho<br>l of the study. Device-re<br>aining 11 participants ha<br>, visual impairmer<br>tion | tem, in persons who are<br>tile stimulation on the to<br>been enrolled across stur-<br>ronments for the next 12<br>ad word identification w<br>social impact of assistiv<br>lated adverse events wil-<br>we been recruited and w<br>nt, assistive device<br>17. LIMITATION<br>OF ABSTRACT | dy is to evaluate th<br>profoundly blind<br>ongue, is designed<br>dy sites. Participar<br>2 months. Function<br>ere assessed at ba<br>e devices and gene<br>1 be reported throu-<br>vill be enrolled wit<br>e, assistive tec<br>18. NUMBER<br>OF PAGES | NUMBER(S)<br>The functional performance of the BrainPort®<br>due to a traumatic injury (cortical or<br>to enhance independence in performing<br>the have received ten hours of device<br>nal performance measures of object<br>seline and post-device training. Follow-up<br>the self-efficacy were assessed at baseline<br>ughout the study to evaluate the risks<br>hin the next quarter.<br>hnology, visual aid, non-surgical<br>19a. NAME OF RESPONSIBLE PERSON<br>USAMRMC<br>19b. TELEPHONE NUMBER (include area |

Standard Form 298 (Kev. 8-9 Prescribed by ANSI Std. Z39.18

# TABLE OF CONTENTS

| Section   | Page No. |
|---|----------|
| 1. Introduction                                     | 4        |
| 2. Keywords   | 4        |
| 3. Accomplishments                                  | 4        |
| 4. Impact   | 9        |
| 5. Changes/Problems                                 | 9        |
| 6. Products   | 9        |
| 7. Participants & Other Collaborating Organizations | 9        |
| 8. Special Reporting Requirements                   | 11       |
| 9. Appendix   | 11       |

### **1. INTRODUCTION:**

The BrainPort V200 device is a wearable, non-surgical, FDA approved, prosthetic device intended for people who are profoundly blind. The BrainPort V200 translates images captured by a digital camera into electrotactile stimulation presented on the user's tongue to perceive shape, size, location, and motion of objects within the environment. The purpose of this study is to evaluate the safety and functional performance of the BrainPort V200 in individuals who have been medically documented as blind, light perception or worse, due to a traumatic injury (cortical or ocular).

### 2. KEYWORDS:

BrainPort, V100, V200, blindness, visual impairment, assistive device, assistive technology, visual aid, non-surgical visual prosthetic, sensory substitution

### 3. ACCOMPLISHMENTS:

### What were the major goals and objectives of the project?

The major goals of this research project are to evaluate the safety and effectiveness of the BrainPort V200 device in individuals who have been blinded by traumatic injury by enabling this population to use and evaluate the BrainPort V200 device in normal operational settings, including at home and in public places. An additional objective of this study is to explore the design and hardware requirements for a population with multiple disabilities (polytrauma). The aim is that the findings from this research will result in a proven assistive technology ready for rapid deployment to wounded warriors, veterans, and civilians who have been blinded by traumatic events.

### What was accomplished under these goals?

Specific Aim 1: Enable individuals blinded by traumatic injury to test and evaluate the BrainPort V200 device in normal operational settings (at home, public places, etc).

#### **Device and Software Development**

While the first year of development of the BrainPort V200 device (Figure 1), the engineering activities in the second year of the study included bug fixes, the SignFinder application installation, and software upgrades following subjects' 6 month assessment visits.




Figure 1: BrainPort® V200

The 'SignFinder' application assists the subjects in locating important signs commonly found in a public setting, specifically EXIT, MEN'S ROOM, and WOMEN'S ROOM signs. Following the subjects' 6 month visit, the devices were sent back to the Wicab, Inc. site for upgrades and returned to the subjects' homes (approximately 2 weeks following their assessment visit). The software upgrades include audio feedback during power up/down process, image invert software fix, improved battery status reporting, headset arms improved, and user controls improved. These upgrades were further detailed in the Y2Q2 technical report.

# Specific Aim 2: Evaluate the safety and efficacy of the BrainPort V200 device on this population.

### Subject Enrollment

To date 22, subjects have been enrolled in the study (14 from Chicago Lighthouse and 8 from Lighthouse Guild). Of these 22 subjects, four are Veterans. To date, four of these subjects have withdrawn from the study dues to reasons of lack of interest in the device or study activities. The subject characteristics for the total study sample are located in Table 1.

| Age (years)                    |                     | Duration of Blindness (years) |                   |
|--------------------------------|---------------------|-------------------------------|-------------------|
| Mean ± SD                      | $40.68 \pm 12.32$   | Mean ± SD (N)                 | $30.8\pm22.5$     |
| [Median] (min, max)            | [40.5] (21.0, 66.0) | [Median] (min, max)           | [8.5] (1.0, 56.0) |
| Gender % (n)                   |                     | Braille Readers               | 63.6% (14)        |
| Women                          | 23% (5)             | Mobility Assistive Device     |                   |
| Men                            | 77% (17)            | Use Any Type                  | 100% (22)         |
| Race % (n)                     |                     | White Cane                    | 100% (22)         |
| American Indian /Alaska Native | 0% (0)              | Guide Dog                     | 27% (6)           |
| Black or African American      | 45.45% (10)         | Sighted Guide                 | 50% (11)          |
| Other                          | 9.1% (2)            |                               |                   |
| White                          | 45.45% (10)         |                               |                   |
| Ethnicity                      |                     |                               |                   |
| Hispanic or Latino             | 9.1% (2)            | ]                             |                   |
| Not Hispanic or Latino         | 90.9% (20)          |                               |                   |

| 1 a U = 1. Subject Characteristics $(11-22)$ | Table 1. | Subject | Characteristics | (n=22) |
|--|----------|---------|-----------------|--------|
|--|----------|---------|-----------------|--------|

# Subject Follow-Up

All 18 subjects who are currently enrolled are in the home usage and follow-up phase of the study. The subjects are expected to use the device for a total of 300 minutes per month and return to the study site every 3 months to undergo assessment testing. In addition, study staff calls administers bimonthly phone calls to troubleshoot problems, encourage subjects to continue to use the device for the required minutes, and assess for adverse events.

All subjects were given access to the online blog at CafePress.com where they can anonymously discuss usage at home with other subjects, share feedback, troubleshooting tips, and offer suggestions for use and device improvement. The site is continuously monitored by the PI.

The study staff trained subjects on how to use the SignFinder application during their 6 month assessment so that they are prepared to use the application in their own environments and at the study sites during their 9 month assessment visits. Assessment on the application will be conducted during subjects' 9 month assessment visits.

### Interim Results – 6 month quarterly assessment

**Safety Objective:** To date, no clinically significant device related adverse events have been reported. Therefore our safety objective has been met at the 6 month time point.

**Object Recognition Tasks (Common Objects and Placing Setting Objects)**: Four high contrast objects are placed on a table 10" apart. The subjects are instructed to use the BrainPort V200 device to identify the object and then grab the target object without touching any other objects first. The objects in the common objects task include a ball, banana, mug, and spoon. The objects in the place setting task include a plate, bowl, glass, and fork. The assessment is deemed as successful if the subject is able to identify five or more objects out of ten trials.

### **Object Recognition Tasks Results**

At baseline, none of the subjects were able to perform either task successfully without the use of the BrainPort V200 device. At 6 months, 100% of the subjects could achieve these 2 tasks beyond chance level, therefore our efficacy objective has been met at the 6 month time point (Figure 2).




Figure 2. Object recognition task success from baseline through 6 months (n=18)

# **Reading Tasks**

The following reading tasks were administered:

**Flashcards:** Ten 3-6 letter words were presented on a standard size flashcard. Subjects were instructed to use the BrainPort V200 to read the words aloud. Successfully reading greater than 5 out of 10 words represents success beyond chance.

**Sign Detection:** This task consisted of a combination of reading and mobility tasks. Four signs were hung in a 20' hallway. Subjects were asked to navigate independently down the hallway and identify and touch the target sign. If the subject touched or came within 5" of touching the target sign, this was recorded as a successful trial. The signs included MEN, WOMEN, STAIRS, and DANGER.

### **Reading Tasks Results**

None of the subjects were able to successfully complete either reading task at baseline, without the use of the BrainPort V200. At the 6 month assessment period, 29% of the subjects were able to complete the flashcard reading task and 38% of subjects are able to complete the Sign ID task (Figure 3).



### Figure 3. Reading tasks success rates from baseline through 6 months (n=18)

### **Orientation and Mobility Tasks**

The orientation and mobility assessment includes several tasks consisting of the following:

- •Following a high contrast line on the floor without veering off
- •Identifying and avoiding an obstacle in their pathway
- •Identifying a window and door in the room
- •Walking through the doorway without colliding with the doorframe.

### **Orientation and Mobility Results**

Similar to other tasks, none of the subjects were able to successfully complete the orientation and mobility tasks at baseline without the BrainPort V200 device. At 6 months, 87% of subject could follow a line without veering off, 64% could identify and avoid an obstacle in their pathway, 93% could recognize a door in the room, 71% could walk through the door without colliding with the doorframe, and 50% could recognize a window in the room. The success rates for baseline, post-training, 3 months, and 6 months are displayed in Figure 4.




Figure 4. Orientation and mobility success rates from baseline through 6 months (n=18)

## FITBIR

The FITBIR form structures for all study data have been created and a data submission is planned for February/March 2017.

### **IRB Status**

The New England IRB approved continuation of the study at all three study sites from the dates of 10/25/2016 - 11/22/2017. The HRPO has been notified of approval.

### What opportunities for training and professional development did the project provide?

The study activities undertaken by Research Associate Tiffany Arango under the direction of Dr. William Seiple at the Lighthouse Guild contributed to her professional growth in the areas of developing research skills through interactions with the site PI, study PI, and research subjects and participating in the successful management of a research agenda. Enhancement of these skills has prepared her for acceptance to the PhD program in the Psychology Department at Northeastern University for the Fall term 2016.

### How were the results disseminated to communities of interest?

The 6 month interim results of this study were presented at the U.S. Department of Veterans Blind Rehabilitation Services National Convention in August 2016 in Milwaukee, WI. Attendees of the presentation included Blind Rehabilitation Outpatient Specialists, Visual Impairment Services Team Coordinators, and other BRS staff from the VA Central Office. The presentation fostered further communications surrounding provision of the BrainPort training in VA Hospitals and BRS Centers. The implementation of BrainPort training is expected to begin at the Central Blind Rehabilitation Center at the Edward Hines Jr. VA Hospital in the near future.

# What do you plan to do during the next reporting period to accomplish the goals and objectives?

The main effort for the next reporting period is to complete all 9 month quarterly assessments and begin 12 month quarterly assessments. The expected achievements for the next reporting period are detailed in Table 1.

| Major Task                                       | SubTask  |
|--|--|
| 1. Human subject protocol and informed consent   | • Continue to monitor for adverse events to report to the IRB.   |
| 2. Site Training                                 | • Assure study staff maintains human subjects training for remainder of study.   |
| <b>3.</b> Participant Recruitment and Evaluation | • Complete 9 month quarterly assessments on begin final assessments.   |
| 4. Coordinate safety and efficacy reporting      | <ul> <li>Monitor study data and communicate with<br/>study sites for reports of adverse events.</li> <li>Monitor social networking website to review<br/>feedback from participants regarding device<br/>use.</li> </ul>                   |
| 5. Data Analysis                                 | <ul> <li>FITBIR data download is planned for<br/>February 2017.</li> <li>Coordinate with study sites to disseminate<br/>study findings at the Association for<br/>Research in Vision and Ophthalmology 2017<br/>annual meeting.</li> </ul> |

Table 1. Scheduled achievements for Year 2- 4<sup>th</sup> Quarter

## 4. IMPACT

To date, study participants have been given the opportunity experience the device in their personal settings and provide valuable feedback on device usage which has contributed to the overall design of the BrainPort V200 device. Our interim results indicate that participants are able to successfully engage in activities of daily living such as object recognition, text identification, and orientation and mobility tasks.

### 5. CHANGES/PROBLEMS

#### Changes in approach and reasons for change

Nothing to report to during this reporting period

### Actual or anticipated problems or delays and actions or plans to resolve them

As noted in Wicab's letter to CDMRP dated August 25, 2016, we are currently delayed in completion of the study by approximately 6 months. Our letter served as notification to a 12-month extension and reallocation of funds.

### Changes that had a significant impact on expenditures

Nothing to report to during this reporting period

# Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents

Nothing to report to during this reporting period

### 6. **PRODUCTS**

### Includes:

- The BrainPort V200 electronic vision aid (described previously) has been developed under this research. FDA clearance to market the V200 in the US is expected by early 2017.
- No inventions, patent applications, or licenses have resulted from this research.
- No other products were developed under this program

## 7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS

### What individuals have worked on the project?

Information for each person who has worked at least one person month per year on the project during the reporting year, regardless of compensation is outlined below.

Name: Patricia Grant
 Project Role: Co-PI: Lead Researcher
 Researcher Identifier (e.g. ORCID ID): N/A
 Nearest person month worked: 6
 Contribution to Project: Ms. Grant has been responsible for overseeing the conduct of the research to ensure consistent adherence to the study protocol across study sites. In addition, she has acted as data monitor, carefully reviewing data and data collection

activities. Lastly, Ms. Grant is also responsible for maintaining IRB and HRPO approval throughout the study. Funding Support: N/A

2. Name: Rich Hogle

Project Role: Co-PI – Lead Engineer Researcher Identifier (e.g. ORCID ID): N/A Nearest person month worked: 4 Contribution to Project: Mr. Hogle has managed the activities of the Engineering team to ensure delivery of devices and associated software. As Lead Engineer, Mr. Hogle has been responsible for the development of the BrainPort V200 from concept through release and support of devices for this research activity. Funding Support: N/A

3. Name: Derald Woods

Project Role: Software Engineer Researcher Identifier (e.g. ORCID ID): N/A Nearest person month worked: 6 Contribution to Project: Mr. Woods has been responsible for the primary software development efforts related to BrainPort V200. Funding Support: N/A

4. Name: Ryan Pope

Project Role: Production Engineer Researcher Identifier (e.g. ORCID ID): N/A Nearest person month worked: 5

Contribution to Project: Mr. Pope has been involved with the BrainPort V200 builds, as well as the packaging and shipping activities involved with the V200 delivery to study sites.

Funding Support: N/A

5. Name: Steve Correll

Project Role: Electrical Engineer Researcher Identifier (e.g. ORCID ID): N/A Nearest person month worked: 1 Contribution to Project: Mr. Correll has been responsible for design and implementation of the electronic hardware architecture for BrainPort V200. Funding Support: N/A

6. Name: Janet Szlyk

Project Role: Site PI Researcher Identifier (e.g. ORCID ID): N/A Nearest person month worked: 1 Contribution to Project: Dr. Szlyk has been responsible for the conduct of the research at the Chicago Lighthouse. Including subject recruitment, device training, documentation, and all study-related procedures. Funding Support: Translation of Eye Movement Training to Clinical Practice, C0849-R. Grant number: 5I01RX000849-02- 5.0 calendar months

7. Name: Meesa Maeng Project Role: Research Associate/BrainPort Trainer Researcher Identifier (e.g. ORCID ID): N/A Nearest person month worked: 3 Contribution to Project: Ms. Maeng has been responsible for all study-related procedures at the Chicago Lighthouse, including subject recruitment and screening, device training, and data collection. Funding Support: Translation of Eye Movement Training to Clinical Practice, C0849-R. Grant number: 5I01RX000849-02 – 4.0 calendar months

8. Name: William Seiple

Project Role: Site PI Researcher Identifier (e.g. ORCID ID): N/A Nearest person month worked: 2 Contribution to Project: Dr. Seiple has been responsible for conduct of the research at the Lighthouse Guild. Including subject recruitment, device training, documentation, and all study-related procedures Funding Support: Translation of Eye Movement Training to Clinical Practice, C0849-R. Grant number: 5I01RX000849-02 – 5.0 calendar months

9. Name: Tiffany Arrango Project Role: Research Associate/BrainPort Trainer Researcher Identifier (e.g. ORCID ID): N/A Nearest person month worked: 3 Contribution to Project: Ms. Arrango has been responsible for all study-related procedures at the Lighthouse Guild, including subject recruitment and screening, device training, and data collection. Funding Support: N/A

# Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?

Tiffany Arango is no longer active study personnel.

### What other organizations were involved as partners?

The partner organizations that have been involved in the project are detailed below. Organization Name: The Chicago Lighthouse for People Who Are Blind and Visually Impaired Location of Organization: Chicago, IL Partner's contribution to the project (identify one or more): Facilities and collaboration (study site)

Organization Name: Lighthouse Guild

Location of Organization: New York, NY

Partner's contribution to the project (identify one or more): Facilities and collaboration (study site)

## 8. SPECIAL REPORTING REQUIREMENTS

The Quad Chart for this reporting period is included in Appendix A.

### 9. APPENDIX

Appendix A: Quad Chart

# APPENDIX A. Safety and Efficacy of the BrainPort V200 Device in Individuals Blinded by Traumatic Injury

DM130076, Assistive Technologies Research Award W81XWH-13-DMRDP-ATRA

**PI:** Patricia Grant. M.S.

Org: Wicab, Inc.

Award Amount: \$1,393,819.84

### Study/Product Aim(s)

<u>Aim1:</u> Enable individuals blinded by traumatic injury to test and evaluate the BrainPort V200 device in normal operational settings (at home, public places, etc.).

<u>Aim 2:</u> Evaluate the safety and efficacy of the BrainPort V200 device on this population.

<u>Aim 3:</u> Explore the design and hardware requirements for a population with multiple disabilities (polytrauma).

#### Approach

Twenty subjects who are profoundly blind due to a traumatic injury will be enrolled into the study. Subjects will receive approximately 10 hours of training in the clinic setting on the BrainPort V200 device and will then be sent home with the device for 12 months to use the device in their environments. Subjects will visit the study sites quarterly to complete efficacy and safety assessments.

# **Timeline and Cost**

| Activities                            | CY | 14 | 15    | 16    |
|---------------------------------------|----|----|-------|-------|
| Subject Recruitment                   |    |    |       |       |
| Evaluation of device safety           |    |    |       |       |
| Evaluation of device efficacy         |    |    |       |       |
| Exploration of design<br>requirements |    |    |       |       |
| Estimated Budget (\$K)                |    |    | \$767 | \$627 |

Updated: 10/24/2016

